Page 13 - Treating Fields News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(0) Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial, conducted in collaboration with MSD (Merck Co., Inc., Kenilworth, NJ, USA). Novocure also announced the members of its scientific steering committee who will provide expert opinions and recommendations regarding enrollment strategies, country distribution, study timelines and other scientific topics. The KEYNOTE-B36 trial will evaluate Tumor Treating Fields (TTFields) together with pembrolizumab for ...

Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trialST. HELIER, Jersey--(BUSINESS WIRE)--$NVCR #lcsm--Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3

Zai Lab Announces Financial Results for Second-half and Full-year 2020 March 01, 2021 07:00 ET | Source: Zai Lab Limited Zai Lab Limited -- Company to Host Conference Call and Webcast Today at 8:00 a.m. ET SHANGHAI and SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today reported financial results for the second half and full year of 2020, along with corporate updates. “2020 was another year of great accomplishment for Zai Lab,” said Dr. Samantha Du, Founder,...

NovoCure (NVCR) Q4 2020 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble. NovoCure (NASDAQ: NVCR) Ladies and gentlemen, thank you for standing by, and welcome to the NovoCure fourth-quarter and full-year 2020 earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. [Operator instructions] I would now like to hand the conference over to your speaker today, Gabrielle Fernandes, director of investor relations. Thank you. Please go ahead, ma'am. Gabrielle Fernandes -...

TRIDENT will test the potential survival benefit of initiating Optune concurrent with radiation therapy in patients with newly diagnosed glioblastoma Preclinical studies demonstrate that Tumor Treating Fields increase